Hos forsøgspersoner med mild, moderat eller stærkt nedsat leverfunktion (Child - Pugh- A- C) var der ingen klinisk signifikante forandringer (maksimalt ~30%) i eksponeringen af vildagliptin.
In subjects with mild, moderate or severe hepatic impairment (Child-Pugh A-C) there were no clinically significant changes (maximum ~30%) in exposure to vildagliptin.